Unknown

Dataset Information

0

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.


ABSTRACT: AIMS:Although substantial progress has been made in understanding of ontogeny of drug metabolism, there is still a gap of knowledge in developmental pharmacogenetics in neonates. We hypothesized that both age and pharmacogenetics might explain the developmental pattern of CYP2C19. We conducted a population pharmacokinetic-pharmacogenetic study to quantify the developmental pharmacogenetics of CYP2C19 in neonates and young infants using omeprazole as a probe drug. METHODS:Pharmacokinetic samples were collected from 51 Caucasian neonates and young infants, who were receiving omeprazole treatment. Population pharmacokinetic-pharmacogenetic analysis of omeprazole and its metabolites was performed using NONMEM. RESULTS:Data fitted a one-compartment parent and metabolite model with first-order absorption and elimination. CYP2C19 and CYP3A4 are predominantly involved in the metabolism of omeprazole despite their relatively low activities compared to adults. The clearance of omeprazole converted to 5-hydroxy-omeprazole (CLOMZ-M1 ) increases with postnatal age. In CYP2C19 poor and intermediate metabolizers, model-predicted CLOMZ-M1 are 12.5% (5-95% percentile: 3-14.9%) and 44.9% (5-95% percentile: 29.9-72.6%) of the value in extensive/ultrarapid metabolizer, respectively. Model-predicted absorption rate constant of omeprazole is 6.93 (5-95% percentile: 3.01-14.61) times higher in ABCB1 homozygous mutant patients, 1.86 (5-95% percentile: 0.86-3.47) times higher in ABCB1 heterozygous patients than that in ABCB1 homozygous wild-type patients. CONCLUSIONS:Developmental pharmacogenetics of CYP2C19 was quantitatively described in neonates and young infants using omeprazole as a probe drug. Our findings emphasize the importance of semiphysiological developmental pharmacokinetic modelling approach when evaluating developmental pharmacogenetics of drugs with multiple routes of biotransformation.

SUBMITTER: Zhao W 

PROVIDER: S-EPMC5903239 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

Zhao Wei W   Leroux Stéphanie S   Biran Valérie V   Jacqz-Aigrain Evelyne E  

British journal of clinical pharmacology 20180309 5


<h4>Aims</h4>Although substantial progress has been made in understanding of ontogeny of drug metabolism, there is still a gap of knowledge in developmental pharmacogenetics in neonates. We hypothesized that both age and pharmacogenetics might explain the developmental pattern of CYP2C19. We conducted a population pharmacokinetic-pharmacogenetic study to quantify the developmental pharmacogenetics of CYP2C19 in neonates and young infants using omeprazole as a probe drug.<h4>Methods</h4>Pharmacok  ...[more]

Similar Datasets

| S-EPMC7010644 | biostudies-literature
| S-EPMC3684819 | biostudies-literature
| S-EPMC5384691 | biostudies-literature
| S-EPMC4189233 | biostudies-literature
| S-EPMC5075068 | biostudies-literature
| S-EPMC2292499 | biostudies-other
| S-EPMC3740059 | biostudies-literature
| S-EPMC8147656 | biostudies-literature
| S-EPMC9252316 | biostudies-literature
| S-EPMC4999604 | biostudies-literature